研究等業績 - その他 - 三浦　昌朋

Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia

Abumiya M.

Medical Oncology ( Medical Oncology )  35 ( 6 )   2018年06月

DOI

Phase II clinical trial of lenalidomide and dexamethasone therapy in Japanese elderly patients with newly diagnosed multiple myeloma to determine optimal plasma concentration of lenalidomide

Kobayashi T.

Therapeutic Drug Monitoring ( Therapeutic Drug Monitoring )  40 ( 3 ) 301 - 309   2018年06月

DOI

The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma

Kobayashi T.

Annals of Hematology ( Annals of Hematology )  97 ( 6 ) 1097 - 1099   2018年06月

DOI

Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients

Numakura K.

Oncotarget ( Oncotarget )  9 ( 38 ) 25277 - 25284   2018年05月

DOI

Influence of CYP3A5 genetic differences in tacrolimus on quantitative interstitial fibrosis and long-term graft function in kidney transplant recipients

Komine N.

International Immunopharmacology ( International Immunopharmacology )  58   57 - 63   2018年05月

DOI

特集 急性白血病の薬物療法のupdate ～最新の診断・治療戦略～ ８.治療薬物モニタリング

三浦昌朋, 高橋直人

医薬ジャーナル ( 医薬ジャーナル社 )  54 ( 5 ) 1244 - 1248   2018年05月

DOI CiNii Research

A comparison of the effects of CYP3A5 polymorphism on tacrolimus blood concentrations measured by 4 immunoassay methods in renal transplant patients

Akamine Y.

Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics )  43 ( 2 ) 181 - 188   2018年04月

DOI

An update on the clinical pharmacokinetics of fexofenadine enantiomers

Akamine Y.

Expert Opinion on Drug Metabolism and Toxicology ( Expert Opinion on Drug Metabolism and Toxicology )  14 ( 4 ) 429 - 434   2018年04月

DOI

Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma

Igarashi R.

Medical Oncology ( Medical Oncology )  35 ( 4 )   2018年04月

DOI

Correlation of plasma concentration and adverse effects of bosutinib: Standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia

Mita A.

Experimental Hematology and Oncology ( Experimental Hematology and Oncology )  7 ( 1 )   2018年04月

DOI

Prediction of tacrolimus exposure by CYP3A5 genotype and exposure of co-administered everolimus in Japanese renal transplant recipients

Kagaya H.

International Journal of Molecular Sciences ( International Journal of Molecular Sciences )  19 ( 3 )   2018年03月

DOI

第Ⅲ部　治療における最近の新薬の位置付け〈薬効別〉～新薬の広場～ 免疫抑制剤

赤嶺由美子, 三浦昌朋

医薬ジャーナル ( 医薬ジャーナル社 )  54 ( 13 ) 519 - 525   2018年02月

DOI CiNii Research

Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients

Abumiya M.

Leukemia Research ( Leukemia Research )  64   42 - 45   2018年01月

DOI

がん治療時に遭遇する薬物相互作用とその対策を考える

三浦 昌朋, 富岡 佳久

日本医療薬学会年会講演要旨集 ( 一般社団法人 日本医療薬学会 )  28 ( 0 ) 352 - 357   2018年

DOI CiNii Research

Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non–small-cell Lung Cancer

Yokota H.

Clinical Lung Cancer ( Clinical Lung Cancer )  18 ( 6 ) e433 - e439   2017年11月

DOI

Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms

Akamine Y.

Annals of Clinical Biochemistry ( Annals of Clinical Biochemistry )  54 ( 6 ) 677 - 685   2017年11月

DOI

Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations

Niioka T.

Clinical and Experimental Nephrology ( Clinical and Experimental Nephrology )  21 ( 5 ) 787 - 796   2017年10月

DOI

Relationship between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N -Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients with Different CYP2C19 Genotypes

Niioka T.

Therapeutic Drug Monitoring ( Therapeutic Drug Monitoring )  39 ( 5 ) 514 - 521   2017年10月

DOI

Therapeutic strategy of tyrosine kinase inhibitors using plasma concentration

Miura M.

Japanese Journal of Clinical Chemistry ( Japanese Journal of Clinical Chemistry )  46 ( 4 ) 277 - 282   2017年10月

Plasma concentration of osimertinib in a non-small cell lung cancer patient with chronic renal failure undergoing hemodialysis

Tamura T.

Lung Cancer ( Lung Cancer )  112   225 - 226   2017年10月

DOI